EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture

Tong-Che Wu, Yun-Jui Tsou, Wen-Tien Wu, Ru-Ping Lee, Jen-Hung Wang, Kuang-Ting Yeh iD

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Tong-Che Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tzu Chi University, Hualien, Taiwan. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporotic Fractures, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Denosumab and zoledronic acid are both effective and easily administrable injectable anti‐osteoporotic medications for postmenopausal women. This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. A cohort of 175 male patients receiving continuous zoledronic acid treatment and a cohort of 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included, and we analyzed the efficacy of treatment by the improvement in bone mineral density (BMD) and the new‐onset low‐energy fracture rate after 5 years of continuous medication. BMD significantly improved after 5 years of medication, and >90% of patients were satisfied with their treatment medication. BMD improved more with denosumab than with zoledronic acid, especially in patients with T‐scores higher than −2.5. Smoking, alcohol abuse, diabetes, and inflammatory polyarthritis were associated with poor improvements in BMD. The incidence rate of new fragile fracture was 4.4% and old age was significantly associated with the incidence rate of new fracture. In summary, our study revealed that denosumab and zoledronic acid both significantly increased BMD among older male patients with high fragility fracture rates over a 5‐year follow‐up period. Early medical treatment and lifestyle adjustment were crucial for improving quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporotic FracturesOsteoporosis, PostmenopausalHumansMaleFemaleAgedZoledronic AcidBone DensityDenosumabIncidenceQuality of Life

Stichwörter der Autor:innen

FRAXdenosumabnew‐onset low‐energy fractureolder male with low bone masszoledronic acid

Substanzen

Zoledronic AcidDenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • School of Medicine, Tzu Chi University, Hualien, Taiwan.
  • Department of Clinical Education, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Department of Orthopedics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.
  • Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Graduate Institute of Clinical Pharmacy, Tzu Chi University, Hualien, Taiwan.

ORCID-Profile: Kuang-Ting Yeh

Zitieren

APA

Wu, T. C., Tsou, Y. J., Wu, W. T., Lee, R. P., Wang, J. H., & Yeh, K. T. (2024). Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2378

Vancouver

Wu TC, Tsou YJ, Wu WT, Lee RP, Wang JH, Yeh KT. Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2378

BibTeX
@article{Wu2024,
  author = {Wu, Tong-Che and Tsou, Yun-Jui and Wu, Wen-Tien and Lee, Ru-Ping and Wang, Jen-Hung and Yeh, Kuang-Ting},
  title = {Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2378}
}
Kostenlos starten →